Search Result

Results for "

Renal anemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) HIF/HIF Prolyl-Hydroxylase (16) PROTACs (1) Reference Standards (2) TGF-beta/Smad (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (7) Endocrinology (3) Inflammation/Immunology (2) Metabolic Disease (9)

Inhibitors & Agonists

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109057

Enarodustat 4 Publications Verification JTZ-951; SAL0951	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
Enarodustat is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC₅₀ of 0.22 μM. Enarodustat has the potential for renal anemia treatment.

HY-12654

Molidustat Maximum Cited Publications 8 Publications Verification BAY 85-3934	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-112144

TP0463518 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Inflammation/Immunology
TP0463518 is an orally active, competitive pan-inhibitor of hypoxia-inducible factor prolyl hydroxylases PHD1/2/3. TP0463518 competitively inhibits human PHD1 (IC₅₀=18 nM), PHD2 (K_i=5.3 nM), and PHD3 (IC₅₀=63 nM), and targets monkey PHD2 with an IC₅₀ of 22 nM. TP0463518 inhibits PHD-catalyzed hydroxylation to stabilize HIFα, thereby upregulating erythropoietin (EPO) expression and enhancing intestinal iron absorption (such as increased DMT-1 and dCYTb expression), improving anemia. TP0463518 is mainly used for the research of renal anemia and inflammatory anemia .

HY-147025

(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine 1 Publications Verification	PROTACs TGF-beta/Smad HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine is a dual target PROTAC that can not only target to the ubiquitination and degradation of Smad3 but also improve the HIF-α protein level. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine has a multi-path anti-fibrosis function and a renal protection function for research of renal anemia. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine can be used for research on prostate cancer and other cancers .

HY-Y0308D

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339	Biochemical Assay Reagents	Endocrinology
Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms .

HY-109057A

Enarodustat hydrochloride JTZ-951 hydrochloride; SAL0951 hydrochloride	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
Enarodustat hydrochloride is a potent and orally active HIF/HIF Prolyl-Hydroxylase inhibitor, with an EC₅₀ of 0.22 μM. Enarodustat hydrochloride has the potential for renal anemia treatment.

HY-W747868

Molidustat sodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat sodium is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat sodium can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat sodium can be utilized in the research of renal anemia .

HY-139855

ZG-2033	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
ZG-2033 (Compound 26) is an orally active HIF-2α agonist that demonstrates nanomolar activity in luciferase reporter gene assays (EC₅₀ = 490 nM). ZG-2033 has the effect of alleviating anemia and exhibits synergistic action with AKB-6548 (HY-101277) in anemia, and can be used in the study of renal anemia .

HY-161660

DS44470011	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Metabolic Disease
DS44470011 is a hypoxia-inducing factor prolyl hydroxylase (HIF-PHD) inhibitor. DS44470011 has oral activity. DS44470011 promotes cell release of erythropoietin (EPO). DS44470011 can be used in the research of renal anemia .

HY-131346

HIF-PHD-IN-1	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
HIF-PHD-IN-1 is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), with an IC₅₀ of 54 nM for hHIF-PHD2. HIF-PHD-IN-1 is promising therapeutic agents for renal anemia .

HY-12654R

Molidustat (Standard) BAY 85-3934 (Standard)	HIF/HIF Prolyl-Hydroxylase Reference Standards	Cardiovascular Disease
Molidustat (Standard) is the analytical standard of Molidustat. This product is intended for research and analytical applications. Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-176408

PHD2-IN-5	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
PHD2-IN-5 (compound 22) is a potent PHD2 inhibitor with an IC₅₀ of 0.82 μM. PHD2-IN-5 can be used in the study of renal anemia .

HY-163839

DS-1093a	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
DS-1093a is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor, with an EC₅₀ of 0.49 μM in Hep3B cell EPO production. DS-1093a can be used in the research of renal anemia .

HY-161265

HIF-2α agonist 3	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
HIF-2α agonist 3 (Compound 14d) is an orally active HIF-2α agonist with a EC₅₀ value of 1.78 μM. HIF-2α agonist 3 can be used in the study of renal anemia .

HY-180164

DS79540454	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Endocrinology
DS79540454 is a HIF-PHD2 inhibitor with an IC₅₀ 0.26 μM. DS79540454 can be used in the research of renal anemia .

HY-179647

ZG-2686	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Endocrinology
ZG-2686 is a potent and selective HIF-2α agonist with an EC₅₀ of 0.25 µM. ZG-2686 exhibits selectivity over PHD2. ZG-2686 binds to a specific internal cavity of HIF-2α, forming hydrogen bonds via structural water molecules, which stabilizes the HIF-2α/β heterodimer and enhances transcriptional activity. ZG-2686 synergizes with Vadadustat (HY-101277) to upregulate HIF-2α-dependent EPO gene expression both in vitro and in vivo. ZG-2686 can be used for the research of renal anemia .

HY-109057R

Enarodustat (Standard) JTZ-951 (Standard); SAL0951 (Standard)	HIF/HIF Prolyl-Hydroxylase Reference Standards	Metabolic Disease
Enarodustat (Standard) is the analytical standard of Enarodustat (HY-109057). This product is intended for research and analytical applications. Enarodustat is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC₅₀ of 0.22 μM. Enarodustat has the potential for renal anemia treatment.

Cat. No.	Product Name	Type

HY-Y0308D

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339	Biochemical Assay Reagents
Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms .

Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339

Disodium hydrogen phosphate, meets analytical specification of Ph. Eur. BP USP FCC E339

Biochemical Assay Reagents

Sodium phosphate dibasic (Disodium hydrogen phosphate), meets analytical specification of Ph. Eur. BP USP FCC E339 is an inorganic dibasic phosphate that functions as an electrolyte supplement, a buffer carrier for injectable drugs, while also exhibiting nephrotoxicity. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 induces extensive nephrotic syndrome-like changes, including systemic symptoms such as persistent proteinuria, lipemia, hypercholesterolemia, and anemia, and causes severe renal pathological alterations such as renal enlargement, glomerular calcification, podocyte injury, and tubulointerstitial lesions. Sodium phosphate dibasic, meets analytical specification of Ph. Eur. BP USP FCC E339 has the ability to induce phosphate-induced nephropathy and glomerular calcification, and can be widely used in studies on nephrotic syndrome and related renal pathological mechanisms .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.